[
  {
    "ts": null,
    "headline": "Ulcerative Colitis Market Poised for Strong Expansion During the Forecast Period (2025-2034) Driven by Biologic and Novel Therapy Adoption Landscape | DelveInsight",
    "summary": "DelveInsight's Ulcerative Colitis Market Insights report includes a comprehensive understanding of current treatment practices, ulcerative colitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan).",
    "url": "https://finnhub.io/api/news?id=65e1cc58120a749c89e814beaf1abc720f52cd5e3892217401762423017eac1f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766010660,
      "headline": "Ulcerative Colitis Market Poised for Strong Expansion During the Forecast Period (2025-2034) Driven by Biologic and Novel Therapy Adoption Landscape | DelveInsight",
      "id": 137816777,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "DelveInsight's Ulcerative Colitis Market Insights report includes a comprehensive understanding of current treatment practices, ulcerative colitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan).",
      "url": "https://finnhub.io/api/news?id=65e1cc58120a749c89e814beaf1abc720f52cd5e3892217401762423017eac1f"
    }
  },
  {
    "ts": null,
    "headline": "Big Pharma stocks 'way undervalued,' says market expert",
    "summary": "STORY: Coons noted that although regulatory changes have \"weighed on some stocks within healthcare... we still like the weight-loss theme, particularly around Lilly.\"The global obesity market has surged in recent years on strong demand for GLP-1-based drugs like Lilly's blockbuster drug Zepbound.Lilly also produces Kisunla, a drug to slow Alzheimer's.\"When you're looking at Big Pharma, they're just way undervalued right now relative to the rest of the market,\" said Coons, who added, \"we do like Merck as well.\"",
    "url": "https://finnhub.io/api/news?id=55f9d1bbd3406c8711a4c1173db089e442da61358734ac32d5d8326f83dd4030",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766006759,
      "headline": "Big Pharma stocks 'way undervalued,' says market expert",
      "id": 137816778,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "STORY: Coons noted that although regulatory changes have \"weighed on some stocks within healthcare... we still like the weight-loss theme, particularly around Lilly.\"The global obesity market has surged in recent years on strong demand for GLP-1-based drugs like Lilly's blockbuster drug Zepbound.Lilly also produces Kisunla, a drug to slow Alzheimer's.\"When you're looking at Big Pharma, they're just way undervalued right now relative to the rest of the market,\" said Coons, who added, \"we do like Merck as well.\"",
      "url": "https://finnhub.io/api/news?id=55f9d1bbd3406c8711a4c1173db089e442da61358734ac32d5d8326f83dd4030"
    }
  },
  {
    "ts": null,
    "headline": "Drug Delivery Devices Market Set to Exceed US$ 450.7 Billion by 2035 as Biologic Revenue Surges Drive Urgent Expansion of Device Manufacturing Capacity Says Astute Analytica",
    "summary": "The market is surging due to the rising prevalence of chronic diseases and a massive shift toward home-based self-administration. The rapid expansion of biologics necessitates advanced injectables, while smart, connected devices are enhancing patient adherence, fueling robust market growth globally.Chicago, Dec. 17, 2025 (GLOBE NEWSWIRE) -- The global drug delivery devices market size was valued at US$ 212.6 billion in 2025 and is projected to reach US$ 450.7 billion by 2035, growing at a CAGR o",
    "url": "https://finnhub.io/api/news?id=081555c572f774d64b4271531c05edcd509e56b9c2f4c339051f8f2892fae292",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765989000,
      "headline": "Drug Delivery Devices Market Set to Exceed US$ 450.7 Billion by 2035 as Biologic Revenue Surges Drive Urgent Expansion of Device Manufacturing Capacity Says Astute Analytica",
      "id": 137816779,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The market is surging due to the rising prevalence of chronic diseases and a massive shift toward home-based self-administration. The rapid expansion of biologics necessitates advanced injectables, while smart, connected devices are enhancing patient adherence, fueling robust market growth globally.Chicago, Dec. 17, 2025 (GLOBE NEWSWIRE) -- The global drug delivery devices market size was valued at US$ 212.6 billion in 2025 and is projected to reach US$ 450.7 billion by 2035, growing at a CAGR o",
      "url": "https://finnhub.io/api/news?id=081555c572f774d64b4271531c05edcd509e56b9c2f4c339051f8f2892fae292"
    }
  },
  {
    "ts": null,
    "headline": "Billionaire With 30 Years of 30% CAGR Gains Dumped Nvidia, Palantir, and Eli Lilly",
    "summary": "Very few investors can match Stanley Druckenmiller. He delivered an average annual return of over 30% over three decades at Duquesne Capital without a single losing year, but he does not own Nvidia (NASDAQ:NVDA), Palantir (NASDAQ:PLTR), and Eli Lilly (NYSE:LLY) today. We’ll look into why in a bit. Druckenmiller is a timeless icon who has ... Billionaire With 30 Years of 30% CAGR Gains Dumped Nvidia, Palantir, and Eli Lilly",
    "url": "https://finnhub.io/api/news?id=28d8598dc41b2f986163c3ab8d8547fce75c3bb8025ad9408d17b914b64623cb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765987518,
      "headline": "Billionaire With 30 Years of 30% CAGR Gains Dumped Nvidia, Palantir, and Eli Lilly",
      "id": 137816780,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Very few investors can match Stanley Druckenmiller. He delivered an average annual return of over 30% over three decades at Duquesne Capital without a single losing year, but he does not own Nvidia (NASDAQ:NVDA), Palantir (NASDAQ:PLTR), and Eli Lilly (NYSE:LLY) today. We’ll look into why in a bit. Druckenmiller is a timeless icon who has ... Billionaire With 30 Years of 30% CAGR Gains Dumped Nvidia, Palantir, and Eli Lilly",
      "url": "https://finnhub.io/api/news?id=28d8598dc41b2f986163c3ab8d8547fce75c3bb8025ad9408d17b914b64623cb"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Issues Soft 2026 View: What Does It Mean for the Stock's Future?",
    "summary": "PFE's soft 2026 outlook spooks investors, with revenue and EPS guidance trailing expectations as COVID-19 demand fades and patent losses mount.",
    "url": "https://finnhub.io/api/news?id=d45dd8a91341fb8f2bd6462374986bfea7a1b9580429d10e83422a4f7e3fee7c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765983540,
      "headline": "Pfizer Issues Soft 2026 View: What Does It Mean for the Stock's Future?",
      "id": 137816781,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "PFE's soft 2026 outlook spooks investors, with revenue and EPS guidance trailing expectations as COVID-19 demand fades and patent losses mount.",
      "url": "https://finnhub.io/api/news?id=d45dd8a91341fb8f2bd6462374986bfea7a1b9580429d10e83422a4f7e3fee7c"
    }
  },
  {
    "ts": null,
    "headline": "NanOlogy Appoints David J. Arthur as Chief Executive Officer to Drive Clinical Development of its Large Surface Area Microparticle (LSAM) Investigational Drug Portfolio",
    "summary": "NanOlogy, LLC, a clinical-stage oncology company, today announced the appointment of David Arthur as Chief Executive Officer.",
    "url": "https://finnhub.io/api/news?id=b3d1f661d180a6824cacba48c3d5cd7df22a71c0be5c65d8d4b6f35916fbe1ea",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765979220,
      "headline": "NanOlogy Appoints David J. Arthur as Chief Executive Officer to Drive Clinical Development of its Large Surface Area Microparticle (LSAM) Investigational Drug Portfolio",
      "id": 137816782,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "NanOlogy, LLC, a clinical-stage oncology company, today announced the appointment of David Arthur as Chief Executive Officer.",
      "url": "https://finnhub.io/api/news?id=b3d1f661d180a6824cacba48c3d5cd7df22a71c0be5c65d8d4b6f35916fbe1ea"
    }
  },
  {
    "ts": null,
    "headline": "The Ultimate High-Yield Drug Stock to Buy With $1,000 Right Now",
    "summary": "It doesn't have the highest yield, but it has enviable dividend coverage and a long history of surviving in a competitive industry.",
    "url": "https://finnhub.io/api/news?id=06f7a6a5736ea3dcfc0cfc65be9da91695de8240065b8d8cbd59ba0a004083c8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765978500,
      "headline": "The Ultimate High-Yield Drug Stock to Buy With $1,000 Right Now",
      "id": 137816783,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "It doesn't have the highest yield, but it has enviable dividend coverage and a long history of surviving in a competitive industry.",
      "url": "https://finnhub.io/api/news?id=06f7a6a5736ea3dcfc0cfc65be9da91695de8240065b8d8cbd59ba0a004083c8"
    }
  },
  {
    "ts": null,
    "headline": "MEDI&GENE Announces Catalyze Agreement with Lilly to Advance Next-Generation Obesity Therapeutics",
    "summary": "MEDI&GENE, a biopharmaceutical company developing therapeutics for metabolic diseases, announced today that it has entered into a Catalyze agreement with Eli Lilly and Company (Lilly) to advance a next-generation therapeutic for obesity.",
    "url": "https://finnhub.io/api/news?id=fdcaf9db1f16443b6dfeca5dabd860c71dba1773646ea76dbea0a2c5c310f5f0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765976400,
      "headline": "MEDI&GENE Announces Catalyze Agreement with Lilly to Advance Next-Generation Obesity Therapeutics",
      "id": 137816784,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "MEDI&GENE, a biopharmaceutical company developing therapeutics for metabolic diseases, announced today that it has entered into a Catalyze agreement with Eli Lilly and Company (Lilly) to advance a next-generation therapeutic for obesity.",
      "url": "https://finnhub.io/api/news?id=fdcaf9db1f16443b6dfeca5dabd860c71dba1773646ea76dbea0a2c5c310f5f0"
    }
  }
]